222 related articles for article (PubMed ID: 20857093)
21. Miconazole oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4.
Grönlund J; Saari TI; Hagelberg N; Neuvonen PJ; Olkkola KT; Laine K
Antimicrob Agents Chemother; 2011 Mar; 55(3):1063-7. PubMed ID: 21173180
[TBL] [Abstract][Full Text] [Related]
22. CYP2D6 genotype dependent oxycodone metabolism in postoperative patients.
Stamer UM; Zhang L; Book M; Lehmann LE; Stuber F; Musshoff F
PLoS One; 2013; 8(3):e60239. PubMed ID: 23555934
[TBL] [Abstract][Full Text] [Related]
23. Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients.
Andreassen TN; Klepstad P; Davies A; Bjordal K; Lundström S; Kaasa S; Dale O
Eur J Clin Pharmacol; 2011 May; 67(5):493-506. PubMed ID: 21140139
[TBL] [Abstract][Full Text] [Related]
24. Oxycodone findings and CYP2D6 function in postmortem cases.
Jakobsson G; Larsson R; Pellè L; Kronstrand R; Gréen H
Forensic Sci Int Genet; 2021 Jul; 53():102510. PubMed ID: 33799050
[TBL] [Abstract][Full Text] [Related]
25. Grapefruit juice enhances the exposure to oral oxycodone.
Nieminen TH; Hagelberg NM; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
Basic Clin Pharmacol Toxicol; 2010 Oct; 107(4):782-8. PubMed ID: 20406214
[TBL] [Abstract][Full Text] [Related]
26. Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia.
Zwisler ST; Enggaard TP; Mikkelsen S; Brosen K; Sindrup SH
Acta Anaesthesiol Scand; 2010 Feb; 54(2):232-40. PubMed ID: 19719813
[TBL] [Abstract][Full Text] [Related]
27. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol.
Laugesen S; Enggaard TP; Pedersen RS; Sindrup SH; Brøsen K
Clin Pharmacol Ther; 2005 Apr; 77(4):312-23. PubMed ID: 15903129
[TBL] [Abstract][Full Text] [Related]
28. Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups.
Liukas A; Kuusniemi K; Aantaa R; Virolainen P; Neuvonen M; Neuvonen PJ; Olkkola KT
Drugs Aging; 2011 Jan; 28(1):41-50. PubMed ID: 21174486
[TBL] [Abstract][Full Text] [Related]
29. Cytochrome P450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications.
Söderberg Löfdal KC; Andersson ML; Gustafsson LL
Drugs; 2013 May; 73(6):533-43. PubMed ID: 23605691
[TBL] [Abstract][Full Text] [Related]
30. Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients.
Fujiwara Y; Toyoda M; Chayahara N; Kiyota N; Shimada T; Imamura Y; Mukohara T; Minami H
PLoS One; 2014; 9(8):e104215. PubMed ID: 25121773
[TBL] [Abstract][Full Text] [Related]
31. Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users.
Schoedel KA; McMorn S; Chakraborty B; Potts SL; Zerbe K; Sellers EM
J Opioid Manag; 2011; 7(3):179-92. PubMed ID: 21823549
[TBL] [Abstract][Full Text] [Related]
32. Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir.
Nieminen TH; Hagelberg NM; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
Eur J Clin Pharmacol; 2010 Oct; 66(10):977-85. PubMed ID: 20697700
[TBL] [Abstract][Full Text] [Related]
33. Gender difference in prescription opioid abuse: A focus on oxycodone and hydrocodone.
Graziani M; Nisticò R
Pharmacol Res; 2016 Jun; 108():31-38. PubMed ID: 27107788
[TBL] [Abstract][Full Text] [Related]
34. Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects.
Boinpally R; Gad N; Gupta S; Periclou A
Clin Ther; 2014 Nov; 36(11):1638-49. PubMed ID: 25236915
[TBL] [Abstract][Full Text] [Related]
35. Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat.
Chan S; Edwards SR; Wyse BD; Smith MT
Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):295-302. PubMed ID: 17973932
[TBL] [Abstract][Full Text] [Related]
36. Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applications.
Fang WB; Lofwall MR; Walsh SL; Moody DE
J Anal Toxicol; 2013; 37(6):337-44. PubMed ID: 23743505
[TBL] [Abstract][Full Text] [Related]
37. Physiologically based pharmacokinetic modelling of oxycodone drug-drug interactions.
Rytkönen J; Ranta VP; Kokki M; Kokki H; Hautajärvi H; Rinne V; Heikkinen AT
Biopharm Drug Dispos; 2020 Feb; 41(1-2):72-88. PubMed ID: 31925778
[TBL] [Abstract][Full Text] [Related]
38. The impact of drug interactions on adverse effects of oral oxycodone in male geriatric patients.
Kim JH; Kim JY; Lee N; Yee J; Gwak HS
J Clin Pharm Ther; 2020 Oct; 45(5):976-982. PubMed ID: 32068910
[TBL] [Abstract][Full Text] [Related]
39. Two separate dose-dependent effects of paroxetine: mydriasis and inhibition of tramadol's O-demethylation via CYP2D6.
Nielsen AG; Pedersen RS; Noehr-Jensen L; Damkier P; Brosen K
Eur J Clin Pharmacol; 2010 Jul; 66(7):655-60. PubMed ID: 20354688
[TBL] [Abstract][Full Text] [Related]
40. Pharmacodynamic effects of oral oxymorphone: abuse liability, analgesic profile and direct physiologic effects in humans.
Babalonis S; Lofwall MR; Nuzzo PA; Walsh SL
Addict Biol; 2016 Jan; 21(1):146-58. PubMed ID: 25130052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]